What Is HSDD? Causes, Diagnosis, and Treatments for Low Libido in Women

What HSDD Actually Means

HSDD stands for Hypoactive Sexual Desire Disorder. It is defined as persistently low or absent sexual desire accompanied by marked personal distress, and it cannot be explained entirely by another medical condition, a relationship problem, or a drug effect. The distress criterion matters: a woman who feels no particular concern about low desire does not meet diagnostic criteria. The DSM-5 merged HSDD into a broader category called Female Sexual Interest/Arousal Disorder (FSIAD), but the International Classification of Diseases (ICD-10 F52.0) and most clinical trial literature still use the HSDD label, so clinicians use both terms interchangeably.

Population data from the National Health and Social Life Survey and subsequent follow-up studies show that distressing low desire affects approximately 8 to 10 percent of premenopausal women and rises to 12 to 28 percent after natural menopause [1]. A 2008 analysis in Obstetrics and Gynecology (N=31,581) placed the prevalence of distressing low desire at 8.9 percent among women aged 18 to 44, reaching 12.3 percent in the 45-to-64 age group [2]. Those numbers make HSDD the most prevalent female sexual dysfunction by a wide margin.

Desire is regulated by a balance between excitatory neurochemicals (dopamine, norepinephrine, melanocortin) and inhibitory ones (serotonin, opioids, endocannabinoids). HSDD tends to arise when the inhibitory side dominates, which is why both FDA-approved drugs target central neurotransmitter pathways rather than genital blood flow [3].

Is Low Libido in Women Hormonal?

Hormones are a major driver, but not the only one. The clearest hormonal contributors are low testosterone, estrogen deficiency, elevated cortisol from chronic stress, and overt thyroid dysfunction.

Testosterone. Women produce testosterone in the ovaries and adrenal glands. Peak serum levels occur around age 20 and fall roughly 50 percent by the mid-forties, even before menopause begins [4]. Surgical menopause (bilateral oophorectomy) causes an abrupt 40 to 50 percent drop in circulating androgens. Multiple randomized controlled trials show a direct correlation between low free testosterone and reduced sexual desire scores on validated instruments like the Profile of Female Sexual Function (PFSF) [5].

Estrogen. Estradiol does not drive desire directly in the way testosterone does, but estrogen deficiency causes vulvovaginal atrophy, reduced lubrication, and dyspareunia (painful sex). Pain is a powerful conditioned inhibitor of desire. The 2022 ACOG Practice Bulletin on genitourinary syndrome of menopause (GSM) notes that vaginal estrogen reliably reduces dyspareunia and, as a consequence, may indirectly improve desire scores [6].

Cortisol. Chronic psychological stress suppresses the hypothalamic-pituitary-gonadal axis at multiple levels. Elevated cortisol reduces luteinizing hormone (LH) pulsatility, blunting both estradiol and testosterone production. A 2015 study in Psychoneuroendocrinology found that women with higher hair cortisol concentrations (a 3-month average) reported significantly lower scores on the Female Sexual Function Index (FSFI) compared to controls (P<0.01) [7].

Thyroid. Both hypothyroidism and hyperthyroidism impair sexual function. The American Thyroid Association recommends TSH testing in women with unexplained fatigue and sexual complaints because subclinical hypothyroidism is present in 5 to 8 percent of reproductive-age women and is easily treated [8].

Non-hormonal contributors include SSRIs and SNRIs (which delay orgasm and blunt desire in up to 40 percent of users), combined oral contraceptives containing ethinyl estradiol plus progestin (which raise sex hormone-binding globulin and reduce free testosterone), beta-blockers, and relationship conflict [9].

How HSDD Is Diagnosed

No blood test diagnoses HSDD. The diagnosis is clinical and requires three elements: (1) persistent low desire lasting at least six months, (2) personal distress, and (3) exclusion of alternative explanations.

The Decreased Sexual Desire Screener (DSDS) is a validated five-question tool suitable for primary care. A positive result on question five ("Would you like your level of sexual desire to be higher?") with distress on question four achieves a sensitivity of 83 percent and specificity of 88 percent for identifying generalized acquired HSDD [10]. The Female Sexual Function Index (FSFI) provides a more detailed 19-item assessment; a total score below 26.55 is considered indicative of female sexual dysfunction [11].

Laboratory workup should include free and total testosterone, sex hormone-binding globulin (SHBG), estradiol, TSH, prolactin, and a fasting metabolic panel. The goal is not to find a testosterone level that "diagnoses" HSDD (no such threshold is validated) but to identify reversible endocrine causes and to establish a baseline before any hormonal treatment begins [12].

FDA-Approved Treatments for HSDD

Flibanserin (Addyi)

Flibanserin is approved by the FDA for premenopausal women with generalized acquired HSDD. It is a daily oral tablet, 100 mg taken at bedtime [13]. The drug acts as a 5-HT1A agonist and 5-HT2A antagonist, effectively shifting the central excitatory-inhibitory balance toward greater desire.

In the three key VIOLET trials submitted for FDA approval (pooled N=2,657), premenopausal women on flibanserin 100 mg daily reported 0.5 to 1.0 additional satisfying sexual events per month compared to placebo, alongside statistically significant improvements in desire scores and reductions in distress scores [14]. The FDA rejected the drug twice before approving it in 2015, citing modest effect sizes and a meaningful side-effect profile: dizziness (11.4%), somnolence (11.2%), and nausea (10.4%). Alcohol use is contraindicated because co-ingestion raises the risk of severe hypotension. An 8-week trial period is considered the minimum before judging therapeutic response [13].

Bremelanotide (Vyleesi)

Bremelanotide, marketed as Vyleesi, is approved for premenopausal women with generalized acquired HSDD. It is an on-demand subcutaneous injection (1.75 mg) given in the abdomen or thigh 45 minutes before anticipated sexual activity, with a maximum of one dose per 24 hours [15].

The drug is a melanocortin receptor agonist (MC1R and MC4R) that modulates dopaminergic signaling in the hypothalamus. In the Phase 3 RECONNECT trials (two studies, combined N=1,247), bremelanotide produced a statistically significant improvement in the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) score versus placebo (mean difference approximately 3.0 points, P<0.001) and a significant increase in the desire domain of the FSFI [16]. Nausea occurred in 40 percent of treated women (versus 1 percent with placebo) and was the primary reason for discontinuation in roughly 6 percent of participants. Transient blood pressure increases (mean +6 mmHg systolic) were observed and resolved within 12 hours; the drug is contraindicated in women with uncontrolled hypertension or cardiovascular disease [15].

How does Vyleesi feel? Women in the RECONNECT trials most commonly described onset of effects within 45 to 60 minutes. The experience is not a spontaneous surge of desire in the absence of any context; instead, participants reported feeling more receptive and less distracted during sexual activity. Nausea, when it occurred, typically peaked around 60 minutes post-injection and resolved within 2 hours. Flushing and a mild headache were also reported by 18 percent of users [16].

Does HRT Increase Libido?

Menopausal hormone therapy (MHT) reliably treats the estrogen-deficiency symptoms that indirectly suppress desire, but its direct effect on desire itself is modest and variable.

The 2022 Menopause Society (formerly NAMS) position statement concludes that systemic estrogen therapy improves sleep quality, reduces vasomotor symptoms, and resolves GSM, all of which may restore conditions under which desire can re-emerge [17]. However, estrogen alone does not consistently raise desire scores on validated instruments in women who have HSDD without significant GSM. Oral estrogen is also problematic because it raises SHBG, which binds free testosterone and may worsen androgen-driven desire deficits. Transdermal estradiol (patches or gels) bypasses first-pass hepatic metabolism and has a neutral or favorable effect on SHBG [18].

The clearest libido benefit from HRT comes when estrogen is combined with testosterone, a combination discussed in the section below.

Can Testosterone Help Women's Libido?

Yes, and this is the most evidence-supported off-label intervention for HSDD in postmenopausal women. The Endocrine Society's 2019 Clinical Practice Guideline states: "We recommend testosterone therapy for postmenopausal women with HSDD" when other causes have been excluded [12]. That language is one of the stronger endorsements in the guideline.

The most comprehensive meta-analysis to date, published in The Lancet Diabetes and Endocrinology (2019), pooled 36 randomized controlled trials (N=8,480) comparing testosterone therapy to placebo or comparator in women. Testosterone significantly improved satisfying sexual events (standardized mean difference 0.36 to 95% CI 0.22 to 0.50), sexual desire (SMD 0.34), arousal (SMD 0.30), orgasm frequency (SMD 0.26), and reduced sexual distress (SMD 0.28), all at P<0.001 [19].

Dose and delivery. No testosterone product is FDA-approved specifically for women in the United States, which means all female testosterone prescribing is off-label. The standard physiological replacement target is a free testosterone level in the upper quartile of the normal premenopausal female range, roughly 0.5 to 2.0 ng/dL free testosterone or 20 to 80 ng/dL total testosterone depending on the assay [12]. Common delivery methods include:

• Compounded transdermal creams (typically 1 to 2 mg/day applied to the inner wrist, forearm, or inner thigh)
• The Intrinsa patch (300 mcg/day; approved in Europe but not the US), used in the landmark Buster 2005 NEJM study
• Low-dose testosterone pellets (inserted subcutaneously every 3 to 5 months)

The NEJM study by Buster et al. (2005, N=562) remains one of the most-cited trials: surgically menopausal women on oral estrogen who received a 300 mcg/day transdermal testosterone patch reported 2.1 additional satisfying sexual events per month compared to 0.7 with placebo (P<0.001), alongside a 49 percent improvement in desire scores [20].

Safety monitoring matters. Supraphysiologic androgen exposure causes acne, hirsutism, and voice changes, and long-term cardiovascular and breast-cancer safety data beyond 2 years remain limited. The Endocrine Society recommends checking total testosterone at 3 to 6 weeks after initiation and every 6 months thereafter, holding the dose if total testosterone exceeds 80 ng/dL [12].

When SSRIs and Oral Contraceptives Are the Real Problem

Drug-induced HSDD is under-recognized and reversible. SSRIs and SNRIs reduce desire in an estimated 30 to 40 percent of women who take them, largely through serotonin-mediated suppression of dopamine pathways and direct genital effects [9]. A 2016 JAMA Internal Medicine analysis found that among women aged 18 to 44 taking SSRIs for depression, sexual dysfunction scores were significantly worse than in non-medicated depressed women, confirming the drug effect independent of the underlying mood disorder [21].

Combined oral contraceptives containing ethinyl estradiol raise SHBG by two- to fourfold, which sharply reduces free testosterone. A crossover study in Contraception (Bancroft et al.) found that women switching from a combined OCP to a progestin-only pill or non-hormonal method showed significant recovery of free testosterone levels and improved self-reported desire over 3 months [22]. Women presenting with low libido who started a new OCP within the prior 6 to 12 months deserve a trial of method change before pursuing pharmacotherapy.

Lifestyle and Non-Pharmacologic Approaches

Validated non-pharmacologic interventions exist and are guideline-recommended as first-line adjuncts regardless of which pharmacologic approach is chosen.

Mindfulness-based cognitive therapy (MBCT) for sexual dysfunction, studied by Dr. Lori Brotto at UBC, produced statistically significant improvements in FSFI desire and arousal scores after an 8-week group program (N=117, P<0.001) [23]. The effect size was comparable to the pharmacologic options above for women whose HSDD had a significant psychological component.

Sex therapy and couples-based psychotherapy are recommended in the 2019 Endocrine Society guideline as co-interventions because relationship distress independently predicts treatment non-response to both flibanserin and testosterone [12]. Aerobic exercise three to four times weekly improves hypothalamic-pituitary-adrenal axis regulation and reduces cortisol, with a corresponding benefit on FSFI scores documented in a 2018 Journal of Sexual Medicine trial (N=78) [24].

Choosing the Right Treatment Path

Premenopausal women with HSDD and no identifiable hormonal driver are candidates for flibanserin or bremelanotide, with the choice depending primarily on preference for a daily versus on-demand regimen and on the patient's tolerance for nausea.

Postmenopausal women who have not yet addressed estrogen deficiency should start with transdermal estradiol plus vaginal estrogen for GSM. If desire remains low after 3 months of adequate estrogenization, adding transdermal testosterone at physiological doses is the next step supported by the strongest evidence base [12, 19].

Women of any age whose HSDD started with an SSRI or combined OCP should have a medication review before any additional pharmacotherapy is prescribed. A 6- to 8-week washout or substitution trial resolves drug-induced HSDD in a meaningful proportion of cases, avoiding unnecessary prescriptions [9].

Any woman with a TSH outside the normal range, a prolactin above 25 ng/mL, or free testosterone below the detectable limit of her assay should have those findings addressed before HSDD-specific treatment is initiated.